We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

MiTy Kids (Metformin in Women With Type 2 Diabetes in Pregnancy Kids Trial)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01832181
Recruitment Status : Recruiting
First Posted : April 15, 2013
Last Update Posted : October 19, 2017
Information provided by (Responsible Party):

Study Description
Brief Summary:

The prevalence of diabetes in pregnancy is rising in all maternal age groups. There is increasing evidence that in-utero exposure to maternal diabetes is associated with an increased risk of obesity and type 2 diabetes in children and adults. There is an urgent need to reduce these increasing rates of obesity and diabetes in subsequent generations.

The MiTy Trial (Metformin in Women with Type 2 Diabetes in Pregnancy Trial) is a CIHR-funded multi-centre, randomized controlled trial of women with type 2 diabetes in pregnancy (sample size n=500). The MiTy Trial is looking to determine the effect of the addition of metformin to a standard regimen of insulin in women with diabetes, on perinatal morbidity and mortality.

The MiTy Kids Trial is a follow-up to the MiTy Trial which will determine whether treatment with metformin during pregnancy in women with type 2 diabetes will lead to a reduction in adiposity and improvement in insulin resistance in the offspring of women with diabetes at 2 years of age.

Condition or disease
Type 2 Diabetes

Study Design

Study Type : Observational
Estimated Enrollment : 450 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Metformin in Women With Type 2 Diabetes in Pregnancy Kids Trial (MiTy Kids)
Study Start Date : April 2013
Estimated Primary Completion Date : July 2021
Estimated Study Completion Date : July 2021

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Groups and Cohorts


Outcome Measures

Primary Outcome Measures :
  1. Adiposity in the offspring [ Time Frame: 24 months ]
    Anthropometric measures: BMI and sum of skinfolds (triceps, subscapular, suprailiac and biceps).

Secondary Outcome Measures :
  1. Sum of skinfolds in the offspring [ Time Frame: 6, 12 and 24 months ]
    Triceps, subscapular, suprailiac and biceps.

  2. Central to peripheral adiposity in the offspring [ Time Frame: 6, 12 and 24 months ]
    Suprailiac to triceps skinfold ratio.

  3. Weight gain, BMI and weight-for-length percentile change over time in critical early periods and overall in the offspring. [ Time Frame: 3, 6, 12, 18 and 24 months ]
    Weight and length.

  4. Overweight and obesity in the offspring [ Time Frame: 3, 6, 12, 18 and 24 months ]
    BMI >85th percentile (overweight) and BMI >97th percentile (obesity) for age and gender from World Health Organization (WHO) growth charts.

  5. Insulin resistance in the offspring [ Time Frame: 24 months ]
    Fasting insulin, fasting insulin-to-glucose ratio, and the Homeostasis Model of Assessment - Insulin Resistance (HOMA-IR).

  6. adipocytokine profile in the offspring [ Time Frame: 24 months ]
    Adiponectin and leptin.

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Offspring of women with type 2 diabetes who participated in the MiTy trial during pregnancy.

Inclusion Criteria:

  • Offspring of women with type 2 diabetes who participated (or are participating) in the MiTy trial.

Exclusion Criteria:

  • Offspring with major congenital anomalies.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01832181

Contact: Ainy Zahid 416-480-6100 ext 87546 MiTyKids@sunnybrook.ca
Contact: Siobhan Tobin 416-480-5631 MiTyKids@sunnybrook.ca

Canada, Ontario
Dr. Denice Feig Recruiting
Toronto, Ontario, Canada
Sponsors and Collaborators
Mount Sinai Hospital, Canada
Sunnybrook Research Institute
Canadian Institutes of Health Research (CIHR)
Principal Investigator: Denice Feig, MD Mount Sinai Hospital, Toronto, Ontario, Canada
More Information

Responsible Party: Mount Sinai Hospital, Canada
ClinicalTrials.gov Identifier: NCT01832181     History of Changes
Other Study ID Numbers: 10-0129-A
First Posted: April 15, 2013    Key Record Dates
Last Update Posted: October 19, 2017
Last Verified: October 2017

Keywords provided by Mount Sinai Hospital, Canada:
Metformin in Women
Type 2 Diabetes Pregnancy

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Pregnancy in Diabetics
Diabetes, Gestational
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Pregnancy Complications
Hypoglycemic Agents
Physiological Effects of Drugs